Thisproductiscarefullyusedinpatientswiththrombocytopeniaandplateletdeficiency,severeliverandkidneydysfunction,uncontrolledhypertension,hypertensiveordiabeticretinopathy.Recentsurgicalpatientsshouldals
Hypersensitivitytodheparinsodiumorotherlowmolecularweightheparinand/orheparin,e.g.aclearhistoryorsuspicionofheparin-inducedimmune-mediatedthrombocytopenia.Acutegastroduodenalulcerandcerebralhemorrhage
Followstandardusage.thefollowingisstandardoperation:Theneedlesafetykitisaplasticneedle"receptacle"thatattachessecurelytothesyringe.Thetwocomponentscombinetomakeaneedlesafetykit.Itisdesignedtohelpmedic
Unstablecoronaryarterydisease,suchasunstableanginaandnon-q-wavemyocardialinfarction:Subcutaneousinjection120IU/kgweight,twicedaily.Themaximumdoseis10000IU/12h.Treatmentshouldlastatleast6daysandmaybeex